Ocugen (OCGN) Short term Debt (2014 - 2026)

Ocugen's (OCGN) quarterly Short term Debt came in at $5.0 million in Q1 2026, up 300.4% on a QoQ basis from $1.2 million in Q4 2025.

Ocugen (OCGN) Short term Debt (2014 - 2026) Analysis & Trends

Ocugen (OCGN) has 12 years of Short term Debt data on file, last reported at $5.0 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (changed N/A YoY) and the FY2025 annual result came in at $1.2 million, down 5.73% from the prior year.
Short term Debt rose to $5.0 million in Q1 2026, from $1.2 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $5.0 million in Q1 2026 to a low of $1.2 million in Q4 2025.
A 4-year average of $1.7 million and a median of $1.3 million in 2024 frame the typical range for Short term Debt.
Annual changes were most pronounced in 2024 — Short term Debt climbed 3.18% — and 2025, when it fell 5.73%.
Tracing OCGN's Short term Debt over 4 years: stood at $1.3 million in 2023, then increased by 3.92% to $1.3 million in 2024, then dropped by 5.73% to $1.2 million in 2025, then surged by 300.4% to $5.0 million in 2026.
The last three Short term Debt figures came in at $5.0 million (Q1 2026), $1.2 million (Q4 2025), and $1.3 million (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Ocugen	457.71 Mn	357.61 Mn	-

Download Data